You're signed outSign in or to get full access.
Opaleye Management Inc.
Opaleye Management Inc. is a Boston-based hedge fund and investment advisory firm founded in 2013. The firm manages over $490 million in assets as of June 2025, with a primary focus on actively investing in publicly traded equity securities, particularly in the healthcare and life sciences sector. Opaleye is led by professional investors and serves institutional and high-net-worth clients.
Investment Strategy
Opaleye Management Inc. primarily focuses on investing in publicly traded equities, with a substantial portfolio concentration in biotechnology, pharmaceuticals, and healthcare companies. The firm is known for its research-driven, active management approach, building concentrated positions based on fundamental analysis and sector expertise. Opaleye frequently adjusts its portfolio based on changing company prospects and market opportunities, with a deep emphasis on high-growth life sciences companies.
Latest 13F Filing Activity
Opaleye Management Inc. filed their most recent 13F report on Jun 30, 2025 disclosing 38 equity positions with a total 13F market value of $494M. The fund increased holdings in Harrow Health Inc., Immunome Inc., Sarepta Therapeutics Inc. among other positions. Opaleye Management Inc. reduced exposure to Palvella Therapeutics Inc., Protara Therapeutics Inc., Anaptys Bio Inc. among others.
Top Holdings
Equity Positions (38)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
H HROW | HARROW HEALTH INC | 24.13% | $119.3M | 3,905,000 | $7.12 | $30.54 | +$14.1M |
E ETON | ETON PHARMACEUTICALS INC | 8.25% | $40.8M | 2,860,000 | $5.51 | $14.25 | +$3.7M |
I IMNM | IMMUNOME INC | 6.64% | $32.8M | 3,529,581 | $9.61 | $9.30 | +$8.9M |
S SNWV | SANUWAVE HEALTH INC | 6.52% | $32.2M | 980,000 | $35.35 | $32.86 | -$2.2M |
L LQDA | LIQUIDIA CORPORATION | 6.24% | $30.8M | 2,475,000 | $10.68 | $12.46 | -$2.5M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more